CRISPR Therapeutics (CRSP) Stock Forecast, Price & News

CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

Is CRISPR Therapeutics a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 6 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics or view top-rated stocks.

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for CRISPR Therapeutics.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) announced its quarterly earnings data on Monday, May, 9th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.94) by $0.38. The company earned $0.94 million during the quarter, compared to analyst estimates of $2.45 million. CRISPR Therapeutics had a net margin of 34.04% and a trailing twelve-month return on equity of 12.77%. CRISPR Therapeutics's revenue for the quarter was up 74.4% compared to the same quarter last year. During the same period last year, the business earned ($1.51) earnings per share.
View CRISPR Therapeutics' earnings history.

What price target have analysts set for CRSP?

14 Wall Street analysts have issued 12 month price objectives for CRISPR Therapeutics' shares. Their forecasts range from $53.00 to $220.00. On average, they anticipate CRISPR Therapeutics' share price to reach $117.85 in the next twelve months. This suggests a possible upside of 115.2% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics or view top-rated stocks among Wall Street analysts.

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the following people:

• Dr. Rodger Novak M.D., Founder, Chairman & Pres (Age 55)
• Dr. Samarth Kulkarni, CEO & Director (Age 43, Pay $1.18M) (LinkedIn Profile)
• Dr. Lawrence Otto Klein Ph.D., Chief Operating Officer (Age 40, Pay $675k)
• Mr. James R. Kasinger, Gen. Counsel & Sec. (Age 50, Pay $648.93k)
• Mr. Shaun Foy, Founder
• Dr. Emmanuelle Marie Charpentier, Co-Founder & Scientific Advisory Board Member
• Dr. Craig C. Mello Ph.D., Scientific Founder & Advisory Board Member
• Dr. Chad Cowan Ph.D., Scientific Founder
• Dr. Matthew Porteus M.D., Ph.D., Scientific Founder & Advisory Board Member (Age 56)
• Dr. Daniel G. Anderson Ph.D., Scientific Founder & Advisory Board Member

Who are some of CRISPR Therapeutics' key competitors?

Some companies that are related to CRISPR Therapeutics include argenx (ARGX), Bio-Techne (TECH), Novozymes A/S (NVZMY), Qiagen (QGEN), Qiagen (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Halozyme Therapeutics (HALO), Ginkgo Bioworks (DNA), Novavax (NVAX), Ablynx (ABLYF), Abcam (ABCM), Vir Biotechnology (VIR) and Denali Therapeutics (DNLI).
View all of CRSP's competitors.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (6.04%), Nikko Asset Management Americas Inc. (5.97%), BlackRock Inc. (2.94%), Loomis Sayles & Co. L P (1.67%), Vanguard Group Inc. (1.57%) and Bellevue Group AG (1.20%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics.

Which major investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., Goldman Sachs Group Inc., Jane Street Group LLC, Bellevue Group AG, Carnegie Capital Asset Management LLC, FinTrust Capital Advisors LLC, Loomis Sayles & Co. L P, and Mirae Asset Global Investments Co. Ltd.. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, Michael John Tomsicek, Rodger Novak, and Samarth Kulkarni.
View insider buying and selling activity for CRISPR Therapeutics or view top insider-selling stocks.

Which major investors are buying CRISPR Therapeutics stock?

CRSP stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., BlackRock Inc., Vanguard Group Inc., Charles Schwab Investment Management Inc., Nikko Asset Management Americas Inc., State Street Corp, Woodline Partners LP, and Frontier Capital Management Co. LLC.
View insider buying and selling activity for CRISPR Therapeutics or or view top insider-buying stocks.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $54.76.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics has a market capitalization of $4.24 billion and generates $914.96 million in revenue each year. The company earns $377.66 million in net income (profit) each year or $3.609990 on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics employs 473 workers across the globe.

What is CRISPR Therapeutics' official website?

The official website for CRISPR Therapeutics is www.crisprtx.com.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at (141) 561-3277 or via email at [email protected].